AFFiRiS AG: Alzheimer's Vaccine Candidate AD02 moves into Clinical Phase II Testing(19 Nov 2009) AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company ...
AFFiRiS atherosclerosis vaccine development receives EU support(29 May 2009) AFFiRiS AG announced that its atherosclerosis vaccine development program is receiving support from the EU's EUROTRANS-BIO call. The supported project - known as CETP Vaccine (ETB-2008-28) - is based on the AFFITOMEŽ technology of AFFiRiS AG and is ...
AFFiRiS reaches milestone in clinical trial of Alzheimer's vaccine(18 Jul 2008) In the clinical phase I trial AFF001, AFFiRiS GmbH has now recruited the 24 Alzheimer patients planned for this trial. The trial aims to investigate the tolerability and safety of an Alzheimer's vaccine (AFFITOPE AD01). In the trial, all patients ...
Affiris expands patent portfolio for Alzheimer's Therapies(29 Feb 2008) Affiris GmbH announced that it has been granted a Europe-wide patent for a new method of reducing the amount of harmful protein deposits (beta-amyloid) in the brains of Alzheimer's patients. A key feature of this method is the cleansing of the ...
Affiris granted European patent for Alzheimer's vaccine(22 Nov 2007) Affiris GmbH has been granted a Europe-wide patent for key elements of its Alzheimer's vaccine. As a result, the company has exclusive rights of use to the peptide sequences for an approach to vaccine development. The tolerability of the first ...
Affiris Begins Clinical Testing of Alzheimer's Vaccine(23 Jul 2007) The Alzheimer's vaccine known as Affitope AD01 from Affiris has now entered the clinical phase of its development. All relevant regulatory and statutory approvals have been secured and this innovative treatment is now being tested on humans for the ...
EU team develops new Alzheimer's vaccine(13 Dec 2006) A recently approved project of the sixth EU Framework Programme MimoVax is focussing on a new target for an Alzheimer's vaccine. The project, coordinated by the Austrian company Affiris GmbH, centres on the use of immune reactions to combat ...
Top
